Background New technology can improve patient safety but also has the potential to introduce new errors and risks into healthcare delivery
Purpose To evaluate the effect of an electronic medication administration record (eMAR) application on the rate of medication errors in medication administration recording (ME-MAR).
Material and methods A before and after, quasi-experimental study was conducted in a university hospital that was implementing the eMAR application. eMAR application implementation took place in March 2014. Data collection was conducted in April 2012 (pre-) and June 2014 (post-) by two pharmacists. The ME-MAR found were clarified by the staff involved to discover the cause. A group of experts in patient safety was set up with the task of reviewing the ME-MAR to classify and determine their potential future risk. ME-MAR were classified according to the taxonomy defined by the Ruiz-Jarabo 2000 group. ME-MAR foermine the deprescription rate after multidisciplinary pharmacotherapy revision.
Material and methods The primary care pharmacist checked chronic treatment through multidisciplinary pharmacotherapy revision with clinical, functional and psychosocial variables, and established recommendations. The physician agreed with the patient preferences, and revised the recommendations through weekly drug safety appointments. The multidisciplinary primary care team (pharmacist, physician, nurse and patient) decided on the deprescription modifications to make. Data collected: demographics, total number of drugs, number of drug related problems, and number and type of benzodiazepines/Z-drugs before and after the revision. Data are expressed as median (Q1–Q3).
Results Patients revised:
125. Age 79.5 (75.8–84.0) years; women 30 (75%). Number of drugs 15 (13–17). Number of drug related problems/patient detected on revision 3 (2.0–3.25). Patients with a benzodiazepine/Z-drug prescribed >6 months 40 (32%) and out of these 9 (22.5%) taking 2 benzodiazepines/Z-drugs. Classification of benzodiazepines/Z-drugs: clonazepam 10 (20.4%); lorazepam 9 (18.4%); alprazolam, diazepam, lormetazepam 8 (16.3%) each; zolpidem 3 (6.1%), loprazolam 2 (4.1%) and 1 (2.0%) bromazepam. Total deprescription interventions: 49. In 4 (10%) patients the deprescription succeeded. Deprescribed drugs: 2 lorazepam, 1 loprazolam and 1 clonazepam. In 8 (20%) other patients benzodiazepine